Bio-Rad EVP Sedat Evran acquires 1,044 vested shares

Q: How many shares did BIO executive Sedat Evran acquire?

Sedat Evran acquired 1,044 shares of Bio-Rad Class A common stock on October 20, 2026, when restricted stock units vested. On the same date, 487 shares were delivered or withheld for payment of exercise price or tax liability at a reported price of $354.50 per share.

Q: What was the vesting schedule for Sedat Evran's BIO restricted stock units?

Sedat Evran was granted 4,176 restricted stock units on October 20, 2023. They vest in four equal annual installments beginning on the first anniversary of the grant date.

The award was granted on October 20, 2023, with four equal annual vesting installments beginning on its first anniversary.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

At Bio-Rad Laboratories, Inc., EVP, Global Supply Chain Sedat Evran reported vesting of 1,044 restricted stock units into 1,044 shares of Bio-Rad Class A common stock on October 20, 2026. Also on that date, 487 shares were delivered or withheld for payment of exercise price or tax liability, at a reported price of $354.50 per share. The derivative entry lists 1,044 restricted stock units following the transaction.

Insider Trade Summary

1,044 shares exercised/converted

Exercise 3 txns

Insider EVRAN SEDAT

Role EVP, Global Supply Chain

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units ^{F2, F3}	1,044	$0.00	$0.00
Exercise	Bio-Rad A Common Stock ^F1	1,044	$0.00	$0.00
Exercise Price or Tax Liability	Bio-Rad A Common Stock	487	$354.50	$173K

Holdings After Transaction: Restricted Stock Units — 1,044 contracts (Direct); Bio-Rad A Common Stock — 4,160.12 shares (Direct)

Footnotes (3)

F1. Shares of Class A common stock acquired on the vesting of restricted stock units.
F2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.
F3. On October 20, 2023, the reporting person was granted 4,176 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Key Figures

Shares acquired on vesting: 1,044 shares Shares delivered or withheld: 487 shares Reported price per share: $354.50 per share +2 more

5 metrics

Shares acquired on vesting 1,044 shares October 20, 2026

Shares delivered or withheld 487 shares For payment of exercise price or tax liability on October 20, 2026

Reported price per share $354.50 per share Code F transaction on October 20, 2026

Restricted stock units following transaction 1,044 restricted stock units Reported derivative position following the October 20, 2026 transaction

Restricted stock units granted 4,176 restricted stock units Granted October 20, 2023

Key Terms

Restricted Stock Units, contingent right, vesting

3 terms

Restricted Stock Units financial

"vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"contingent right to receive one share"

vesting financial

"vesting in four equal annual installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did BIO executive Sedat Evran acquire?

Sedat Evran acquired 1,044 shares of Bio-Rad Class A common stock on October 20, 2026, when restricted stock units vested. On the same date, 487 shares were delivered or withheld for payment of exercise price or tax liability at a reported price of $354.50 per share.

What was the vesting schedule for Sedat Evran's BIO restricted stock units?

Sedat Evran was granted 4,176 restricted stock units on October 20, 2023. They vest in four equal annual installments beginning on the first anniversary of the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 10/22/2026 - 05:55 PM EDT Accepted by SEC EDGAR 10/22/2026 - 05:55 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

EVRAN SEDAT

(Last)

(First)

(Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DRIVE

(Street)

HERCULES

CALIFORNIA

94547

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Global Supply Chain

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Bio-Rad A Common Stock	10/20/2026	10/20/2026	M		1,044⁽¹⁾	A	$0	4,647.12	D
Bio-Rad A Common Stock	10/20/2026	10/20/2026	F		487	D	$354.5	4,160.12	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0⁽²⁾	10/20/2026	10/20/2026	M			1,044	⁽³⁾	⁽³⁾	Bio-Rad A Common Stock	1,044	$0	1,044	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

3. On October 20, 2023, the reporting person was granted 4,176 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Sedat Evran	10/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR